Bruton Tyrosine Kinase Inhibitors for B-cell Malignancies
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
- Sex
- Any
- Study type
- Observational
- Participants needed
- 100 (estimated)
- Sponsor
- Mayo Clinic · Other
This trial is looking for patients with certain blood cancers who are starting treatment with specific medications called Bruton tyrosine kinase inhibitors. Participants will be monitored for changes in their blood pressure during the treatment.
You may be able to join if
- I have chronic lymphocytic leukemia
- I have mantle cell lymphoma
- I have Waldenstrom macroglobulinemia
- I have marginal zone lymphoma
- I am planning to begin treatment with Bruton tyrosine kinase inhibitors
- I am willing to return to the Mayo Clinic for follow-up
You may not be able to join if
- I have known central nervous system involvement of my B-cell malignancy
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThis study evaluates the incidence and management of new and worsening high blood pressure in patients with B-cell cancers on BTKi treatment.
Loading trial locations…